Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Rathkopf, D. E., Patel, M. R., Choudhury, A., Rasco, D. W., Lakhani, N. J., Hawley, J. E., Aparicio, A., Narayan, V., Srinivas, S., Runcie, K., Emamekhoo, H., Reichert, Z. R., Carducci, M., Wells, A. L., Liu, C., Kandimalla, R., Wu, J., Nguyen, M., Pourdehnad, M., Armstrong, A. J. LIPPINCOTT WILLIAMS & WILKINS. 2024: 134View details for DOI 10.1200/JCO.2024.42.4_suppl.134
View details for Web of Science ID 001266676900560